Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Universal Method to Mount on the End of Most Commercial Colonoscopes

FORT LAUDERDALE, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued two key new patents that further protect the Company’s flagship product – the Pure-Vu® System – in these key markets.

“We are pleased to announce the strengthening of long-term IP protections in the U.S. and EU for certain innovative technologies that help comprise the backbone of our Pure-Vu System. This includes a U.S. patent for our universal method to mount the Pure-Vu sleeve on nearly all commercial colonoscopes in a manner that creates a secure connection, allowing the scope and the sleeve to work seamlessly together to provide improved visualization during a colonoscopy,” said Tim Moran, chief executive officer of Motus GI. “The commercial potential of our system is more apparent than ever as our U.S. sales program continues to successfully build awareness for the Pure-Vu System among leading U.S. gastroenterologists and hospital systems. In addition, we believe the European market may represent a significant opportunity for the Pure-Vu System if we expand commercialization efforts outside the U.S., either through direct sales or a distribution partnership.”

U.S. Patent
The United States Patent Office issued patent 10,881,277, which is titled “Distal Front End for Coordinated Portioning of an Endoscope with Suction Device.”

European Patent
The EPO issued patent number 3128893, which is titled “Fecal Waste Evacuation Channel.”

About the Pure-Vu System
The Pure-Vu System integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. Challenges with bowel preparation for inpatient colonoscopy, particularly patients who are elderly, with comorbidities, or active bleeds, represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care. Motus GI believes the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon for a quality exam the first time. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen. Motus GI estimates that approximately four million inpatient colonoscopy procedures take place worldwide each year.

The Pure-Vu System has received a CE Mark in the EU and is cleared by the U.S. Food and Drug Administration to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

About Motus GI 

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on TwitterLinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 30, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.